RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs

• Tyler J. W. Robinson ,

  * E-mail: tyler.robinson@mail.utoronto.ca (TJWR); eldad.zacksenhaus@utoronto.ca (EZ)

  Affiliation Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

  ⨯
• Jeff C. Liu,

  Affiliation Division of Advanced Diagnostics, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Frederick Vizeacoumar,

  Affiliation S.M.A.R.T. High Throughput Facility, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada

  ⨯
• Thomas Sun,

  Affiliation S.M.A.R.T. High Throughput Facility, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada

  ⨯
• Neil Maclean,

  Affiliation Clinical Studies Resource Centre, OCI, University Health Network, Toronto, Ontario, Canada

  ⨯
• Sean E. Egan,

  Affiliation Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

  ⨯
• Aaron D. Schimmer,

  Affiliation Clinical Studies Resource Centre, OCI, University Health Network, Toronto, Ontario, Canada

  ⨯
• Alessandro Datti,

  Affiliations S.M.A.R.T. High Throughput Facility, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy

  ⨯
• Eldad Zacksenhaus

  * E-mail: tyler.robinson@mail.utoronto.ca (TJWR); eldad.zacksenhaus@utoronto.ca (EZ)

  Affiliations Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, Division of Advanced Diagnostics, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada

  ⨯